Zobrazeno 1 - 10
of 754
pro vyhledávání: '"Bruce E Sands"'
Autor:
Sarah M Goodday, Emma Karlin, Alexa Brooks, Carol Chapman, Christiana Harry, Nelly Lugo, Shannon Peabody, Shazia Rangwala, Ella Swanson, Jonell Tempero, Robin Yang, Daniel R Karlin, Ron Rabinowicz, David Malkin, Simon Travis, Alissa Walsh, Robert P Hirten, Bruce E Sands, Chetan Bettegowda, Matthias Holdhoff, Jessica Wollett, Kelly Szajna, Kallan Dirmeyer, Anna Dodd, Shawn Hutchinson, Stephanie Ramotar, Robert C Grant, Adrien Boch, Mackenzie Wildman, Stephen H Friend
Publikováno v:
Journal of Medical Internet Research, Vol 26, p e57827 (2024)
BackgroundWearable digital health technologies and mobile apps (personal digital health technologies [DHTs]) hold great promise for transforming health research and care. However, engagement in personal DHT research is poor. ObjectiveThe objective o
Externí odkaz:
https://doaj.org/article/5e84f318bf6a46d793a1a2a87e064a7b
Autor:
Robert P Hirten, Matteo Danieletto, Kyle Landell, Micol Zweig, Eddye Golden, Renata Pyzik, Sparshdeep Kaur, Helena Chang, Drew Helmus, Bruce E Sands, Dennis Charney, Girish Nadkarni, Emilia Bagiella, Laurie Keefer, Zahi A Fayad
Publikováno v:
JMIR Mental Health, Vol 11, p e55552 (2024)
BackgroundHeart rate variability (HRV) biofeedback is often performed with structured education, laboratory-based assessments, and practice sessions. It has been shown to improve psychological and physiological function across populations. However, a
Externí odkaz:
https://doaj.org/article/7711a01fa4e54d3396b8507eb9b4be5b
Autor:
Brian G Feagan, Toshifumi Hibi, Vipul Jairath, Nathan Morris, Bruce E Sands, Marla C Dubinsky, Vipin Arora, April N Naegeli, Trevor Lissoos, Mingyang Shan, Jay Tuttle, Noah Agada
Publikováno v:
BMJ Open Gastroenterology, Vol 10, Iss 1 (2023)
Objective Mirikizumab, a monoclonal antibody targeting the interleukin-23 p19 subunit, was effective in a Phase 2 study (NCT02589665) of moderately-to-severely active ulcerative colitis (UC). We studied mirikizumab’s impact on health-related qualit
Externí odkaz:
https://doaj.org/article/d32d694829724ced8385109aced67187
Autor:
Robert P Hirten, Matteo Danieletto, Lewis Tomalin, Katie Hyewon Choi, Micol Zweig, Eddye Golden, Sparshdeep Kaur, Drew Helmus, Anthony Biello, Renata Pyzik, Claudia Calcagno, Robert Freeman, Bruce E Sands, Dennis Charney, Erwin P Bottinger, James W Murrough, Laurie Keefer, Mayte Suarez-Farinas, Girish N Nadkarni, Zahi A Fayad
Publikováno v:
Journal of Medical Internet Research, Vol 23, Iss 9, p e31295 (2021)
BackgroundThe COVID-19 pandemic has resulted in a high degree of psychological distress among health care workers (HCWs). There is a need to characterize which HCWs are at an increased risk of developing psychological effects from the pandemic. Given
Externí odkaz:
https://doaj.org/article/3f37a1c7c6014379848f566547428423
Publikováno v:
RMD Open, Vol 7, Iss 2 (2021)
Objectives To analyse adverse events (AEs) of special interest across tofacitinib clinical programmes in rheumatoid arthritis (RA), psoriatic arthritis (PsA), ulcerative colitis (UC) and psoriasis (PsO), and to determine whether the incidence rates (
Externí odkaz:
https://doaj.org/article/2abb901d7ddd4948a0902b36ec44f8eb
Autor:
Bruce E Sands, Paul C Adams
Publikováno v:
Canadian Journal of Gastroenterology, Vol 21, Iss 12, Pp 791-793 (2007)
Externí odkaz:
https://doaj.org/article/a7d930045097410baf5cc126d7b62ac0
Autor:
Bruce E Sands
Publikováno v:
Canadian Journal of Gastroenterology, Vol 14, Iss Suppl C, Pp 33C-37C (2000)
Glucocorticosteroids are commonly used in the treatment of moderate to severe Crohn’s disease and are effective for the short term amelioration of symptoms. However, not all patients respond to corticosteroid therapy. Approximately 20% of patients
Externí odkaz:
https://doaj.org/article/219003ba633c48309d4cd9cc5bbbfca6
Publikováno v:
Alimentary Pharmacology & Therapeutics. 57:1216-1230
Autor:
William J Sandborn, Séverine Vermeire, Laurent Peyrin-Biroulet, Marla C Dubinsky, Julian Panes, Andres Yarur, Timothy Ritter, Filip Baert, Stefan Schreiber, Sheldon Sloan, Fabio Cataldi, Kevin Shan, Christopher J Rabbat, Michael Chiorean, Douglas C Wolf, Bruce E Sands, Geert D'Haens, Silvio Danese, Martina Goetsch, Brian G Feagan
Publikováno v:
The Lancet, 401(10383), 1159-1171. Elsevier Limited
BACKGROUND: Etrasimod, a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively activates S1P receptor subtypes 1, 4, and 5, with no detectable activity on S1P2,3, is in development for the treatment of immune-mediated di
Autor:
Brian G Feagan, Bruce E Sands, William J Sandborn, Matthew Germinaro, Marion Vetter, Jie Shao, Shihong Sheng, Jewel Johanns, Julián Panés, Alexander Tkachev, Dilara Kalimullina, Robert Petryka, Marina Osipenko, Nataliia Tsarynna, Leonid Bilianskyi, Dariusz Kleczkowski, Andrii Yurkiv, Marek Woynarowski, Orest Abrahamovych, Olha Ivanishyn, Grazyna Rydzewska, Jaroslaw Kierkus, Elina Petrova, Olga Vasilevskaya, Halyna Afanasieva, Carlos Francesconi, Jaroslaw Leszczyszyn, Elena Bunkova, Dmitry Platonov, Olena Datsenko, Oleksii Gridnyev, Ihor Hospodarsky, Liudmyla Prystupa, Mykola Stanislavchuk, Anatoly Pershko, Oksana Shchukina, Vladimir Simanenkov, Oleksandr Golovchenko, William Holderman, Juan Lasa, Jakob Begun, Maria de Lourdes de Abreu Ferrari, Pedro Lopez, Andrey Obrezan, Shiraz Farooq, Felix Tiongco, Abel Novillo, Emiliano Tron, Finlay Macrae, Rupert Leong, Ligia Yukie Sassaki, Cyrla Zaltman, Roberto Kaiser Junior, Andreas Stallmach, Jochen Klaus, Manuel Martinez, Azalia Ruiz, Rustem Abdulkhakov, Vishvinder Sharma, Louis Korman, James Lord, Bhaktasharan Patel, Timothy Ritter
Publikováno v:
The Lancet Gastroenterology & Hepatology. 8:307-320